Lixte Biotechnology

About:

Lixte Biotechnology is a clinical-stage pharmaceutical company that focuses on discovering drugs for effective cancer treatments.

Website: http://www.lixte.com

Description:

Lixte Biotechnology is a clinical-stage public pharmaceutical company that focuses on discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.

Total Funding Amount:

$10.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

East Setauket, New York, United States

Founded Date:

2004-01-01

Contact Email:

eforman(AT)lixte.com

Founders:

John S. Kovach

Number of Employees:

1-10

Last Funding Date:

2022-04-12

IPO Status:

Public

Industries:

© 2025 bioDAO.ai